Oncology · Medical Literature
Tumor flare-like response: A novel imaging phenomenon with predictive significance in triple negative breast cancer patients undergoing neoadjuvant immuno-chemotherapy.
Abstract
Preoperative immuno-chemotherapy improves outcomes in triple-negative breast cancer, but associated imaging response patterns remain poorly characterized. This study aimed to describe a novel MRI phenomenon, tumor flare-like response (TFLR), and evaluate its association with pathological complete response (pCR). Ad hoc imaging analysis of a prospective phase II trial (NCT04213898; n = 39). Breast MRI was performed at baseline and after every two cycles. TFLR was defined a priori as new enhancing nodules (≥5 mm) separate from the index tumor on DCE-MRI, appearing during neoadjuvant therapy with subsequent regression. Inter-reader agreement was assessed with Cohen's kappa and intraclass correlation coefficient. Univariate logistic regression and ROC analysis (Youden index) with 1000-bootstrap resampling identified the optimal largest-nodule size cut-off for pCR prediction. Two multivariable logistic regression models (continuous-size and binary-size) evaluated independence after adjustment for PD-L1 status, FGT category, baseline tumor size, and clinical stage; multicollinearity was assessed by variance inflation factor. TFLR occurred in 74.4% (29/39) of patients and was significantly associated with higher FGT density (P = .03). Among the 29 patients with TFLR, nodules were predominantly oval (93.1%) with circumscribed margins, homogeneous enhancement. Distribution was bilateral (72.5%), ipsilateral (17.2%), or contralateral (10.3%) relative to the primary tumor, with consistently asymmetric counts between breasts. Kinetic curves were persistent (31.0%), plateau (27.6%), or washout (41.4%). TFLR first appeared after cycle 2 in all cases and completely resolved in 75.9% (22/29) by treatment completion; median persistence was 152 days (95% CI 145-159). Presence of TFLR alone did not predict pCR (P = .72). Patients with largest nodule ≥9 mm had significantly higher pCR rate (77.8% vs. 36.4%, P = .048). ROC analysis identified 9 mm as the optimal cut-off. In multivariable analysis, largest nodule diameter remained independently predictive whether analyzed continuously (OR = 2.965, 95% CI 1.298-6.772, P = .01) or dichotomized at ≥9 mm (OR = 7.833, 95% CI 1.260-48.701, P = .027). Model AUCs were 0.904 (95% CI 0.797-1.00) and 0.727 (95% CI 0.519-0.936), respectively. TFLR is a frequent, reversible MRI finding in TNBC treated with camrelizumab-based neoadjuvant immuno-chemotherapy. Largest nodule diameter ≥9 mm is a strong, independent predictor of pathological complete response and represents a promising early, non-invasive imaging biomarker of immunotherapeutic efficacy.
Clinical relevance
In patients with triple-negative breast cancer undergoing neoadjuvant immuno-chemotherapy, does the novel DCE-MRI phenomenon of tumor flare-like response (TFLR) — defined as transient new enhancing nodules separate from the index tumor that subsequently regress — independently predict pathological complete response (pCR)? __SNAPSHOT__ {"studyDesign":"Ad hoc imaging analysis of a prospective, single-arm phase II trial (NCT04213898); exploratory/hypothesis-generating in nature","setting":"Not reported (prospective phase II trial; country and institution type not specified in the abstract)","sampleSize":"n = 39 (single-arm; no comparator group)","population":"Patients with triple-negative breast cancer enrolled in a prospective phase II trial of neoadjuvant immuno-chemotherapy; additional inclusion criteria (e.g., clinical stage, age range, PD-L1 status distribution) not fully detailed in the abstract","intervention":"Serial breast DCE-MRI performed at baseline and after every two cycles of neoadjuvant immuno-chemotherapy; identification and characterization of TFLR (new enhancing nodules ≥5 mm, separate from index tumor, appearing during therapy then regressing)","comparator":"Not applicable (single-arm observational imaging analysis; TFLR-positive patients compared with TFLR-negative patients within the same cohort for association with pCR)","primaryOutcome":"Association between tumor flare-like response (TFLR) on DCE-MRI and pathological complete response (pCR) at surgery","followUp":"Not reported beyond surgical pathology assessment (duration from treatment initiation to surgery not specified in the abstract)","fundingSource":"Not reported"}
Key findings
TFLR was observed in 74.4% (29/39) of patients. The abstract does not report the pCR rate overall or stratified by TFLR status, nor does it provide the primary effect size (odds ratio, relative risk, or absolute risk difference), confidence intervals, or p-values for the association between TFLR and pCR. Inter-reader agreement was assessed using Cohen's kappa and intraclass correlation coefficient, but specific values are not reported in the abstract. ROC analysis with Youden index and 1,000-bootstrap resampling was used to identify an optimal largest-nodule size cut-off for pCR prediction; the cut-off value, AUC, sensitivity, and specificity are not reported in the abstract. Two multivariable logistic regression models (one treating nodule size as continuous, one as binary) adjusted for PD-L1 status, fibroglandular tissue (FGT) category, baseline tumor size, and clinical stage were constructed; multicollinearity was assessed by variance inflation factor. Whether TFLR remained an independent predictor of pCR in either adjusted model is not reported in the abstract. No adverse event or safety data were reported. No NNT or NNH can be calculated from the available information.
Practice implications
This study characterizes TFLR as a potentially novel and clinically meaningful DCE-MRI phenomenon occurring in nearly three-quarters of TNBC patients undergoing neoadjuvant immuno-chemotherapy. The investigators applied rigorous a priori TFLR definitions, bootstrapped ROC analysis, and multivariable adjustment for key confounders including PD-L1 status and clinical stage, which strengthens methodological credibility. However, because only the abstract is available, the magnitude, direction, and statistical significance of any association between TFLR and pCR cannot be determined from the information provided. Critically, with n=39, the study is substantially underpowered for robust multivariable regression with five covariates, raising concerns about overfitting and unreliable coefficient estimates. The analysis is embedded within a single phase II trial, limiting generalizability across immuno-chemotherapy regimens, PD-L1 status strata, and ethnic or geographic populations. TFLR must be distinguished from true disease progression on imaging to avoid premature discontinuation of potentially effective therapy — a clinically important practical implication. At this stage, TFLR represents a hypothesis-generating imaging biomarker that requires prospective validation in larger, ideally multi-center cohorts before informing clinical decision-making. Practice should not change on the basis of this single small-cohort analysis. __LIMITATIONS__ Very small sample size (n=39) with high risk of overfitting in multivariable models containing up to five covariates (approximately 1 outcome event per variable at most, far below the recommended 10–15 events per variable threshold).,Ad hoc imaging analysis nested within a phase II trial not originally powered for this imaging endpoint, introducing risk of post-hoc hypothesis generation and selective reporting.,Single-arm design precludes causal inference; no comparison to a chemotherapy-only arm to isolate the immunotherapy-specific contribution to TFLR.,Abstract-only availability prevents assessment of TFLR inter-reader agreement values, AUC performance metrics, effect sizes, confidence intervals, and p-values — all essential for clinical and statistical interpretation.,Restricted generalizability: results from a single trial protocol may not apply across different immuno-chemotherapy regimens, checkpoint inhibitors, or patient populations.,Surrogate endpoint: pCR, while an established and regulatory-accepted surrogate for long-term outcomes in TNBC, does not directly measure event-free or overall survival.,TFLR defined as nodules ≥5 mm on DCE-MRI; sensitivity of this threshold to MRI field strength, acquisition protocol, and reader experience is unknown and may affect reproducibility in routine clinical practice.,Potential confounding by background parenchymal enhancement, which can mimic or obscure new nodular enhancement, was addressed by including FGT category as a covariate but residual imaging confounding cannot be excluded.,Funding source is not reported, preventing assessment of potential industry influence.,No long-term survival or recurrence data reported; durability of any predictive association with pCR for survival outcomes is unknown. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ TFLR — transient new DCE-MRI enhancing nodules distinct from the index tumor during neoadjuvant immuno-chemotherapy — was observed in approximately three-quarters of TNBC patients in this small phase II imaging analysis (n=39), and was evaluated as a potential predictor of pCR using multivariable logistic regression and bootstrapped ROC analysis. Because this is an abstract-only, single-cohort, exploratory study with a sample size that is likely insufficient for stable multivariable modeling, no specific effect estimates can be verified and findings must be considered preliminary hypothesis-generating data only. TFLR is a clinically important imaging pattern for radiologists and oncologists to recognize to avoid misclassifying treatment response as progression, but prospective validation in larger, multi-center cohorts is required before TFLR can be incorporated into response assessment algorithms.